Entity

Time filter

Source Type

Karnataka, India

Yadav V.,Banaras Hindu University | Chatterjee S.S.,Stettiner Strae 1 | Majeed M.,Sami Labs Ltd | Kumar V.,Banaras Hindu University
Journal of Traditional and Complementary Medicine | Year: 2015

Aim: To compare stress resistance increasing and analgesic activities of piperlongumine and a methanolic Piper longum fruit extract (PLE). Methods: Efficacies of a single and repeated daily oral doses (1-256 mg/kg/day) of PLE, piperlongumine, and 50 mg/kg/day doxycycline against foot shock stress triggered alteration in body weights and core temperatures, and of their 11 daily doses on antidepressants like activity in tail suspension test and on pentobarbital induced sedation in male mice were compared. In another experiment, analgesic activities of single and repeated daily 5 mg/kg oral doses of piperlongumine and PLE in mice hot plate test and in acetic acid induced writing tests were compared with those of aspirin and doxycycline. Results: After their single oral doses no effects of piperlongumine or PLE or doxycycline were observed in the footshock stress induced hyperthermia test or in hot plate test. However, significant effects of piperlongumine and PLE in both the tests were observed after their 5 or more daily doses. Both of them also dose dependently suppressed daily handling and repetitive testing triggered alterations in body weights and core temperatures. Their doxycycline like antidepressant activity in tail suspension test and aspirin like analgesic effects in acetic acid writhing test were observed after their 11 daily 5 mg/kg oral dose. Conclusion: Piperlongumine is another bioactive secondary metabolite of P. longum and other plants of piper species with stress response suppressing, analgesic, and anti-inflammatory activities. Its bactericidal activities can also contribute to its therapeutically interesting bio-activity profile. © 2015 Center for Food and Biomolecules, National Taiwan University. Source


Chiu S.S.,Lawson Health Research Institute | Majeed M.,Sabinsa Corporation | Majeed M.,Sami Labs Ltd | Vishwanatha J.K.,University of North Texas | And 5 more authors.
Anticancer Research | Year: 2011

Background: The neuropathic side-effects of trauma, stroke or therapeutic radiation of the brain for life-threatening neoplastic diseases are the result of damage to normal tissues resulting in defects in cognition and memory. Based upon published preclinical data of curcumin activity application of parenteral curcumin formulations may prove to be to be promising chemotherapy for disorders following neuropathic insults. Studies in in vitro and animal models suggest curcumin may be an effective remediative agent for brain damage. The initial steps in curcumin development for clinical applications to neuropathic disorders are formulating it for intravenous administration, determining the formulated product passes the blood-brain barrier and reaches therapeutic amounts in damaged areas in the brain with tolerable safety. Following intravenous administration of liposomal curcumin, polymeric nanocurcumin and polylactic glycolic acid co-polymer (PLGA)-curcumin in rats, these formulations were observed to cross the blood-brain barrier using a sensitive HPLC assay. All three formulations localized in specific sites in the brain without observable adverse events. One hour following intravenous injection of 5 mg/kg nanocurcumin, or 20 mg/kg PLGA-curcumin, or liposomal curcumin, up to 0.5% of the injected material localized in the brain stem, the striatum, and the hippocampus with varied accumulation and clearance rates. Conclusion: These data indicate that curcumin does localize in putative damaged brain tissues and suggest therapeutic trials be explored with all three formulations in animal models with pre- and post traumatic states. Source


Trademark
Sami Labs Ltd | Date: 2013-05-02

Dietary and nutritional supplements.


Lai C.-S.,National Taiwan University of Science and Technology | Liao S.-N.,National Kaohsiung Marine University | Tsai M.-L.,National Kaohsiung Marine University | Kalyanam N.,Sabinsa Corporation | And 6 more authors.
Molecular Nutrition and Food Research | Year: 2015

Scope: Diet-induced obesity and associated nonalcoholic fatty liver disease have increased and become a major health problem worldwide. This study was conducted to investigate the chemopreventive effects of dietary Calebin-A, a curcuminoid, on differentiation of 3T3-L1 adipocytes and high-fat diet (HFD) induced obesity and hepatic steatosis. Potential mechanisms contributing to these effects were also elucidated. Methods and results: Calebin-A effectively and dose dependently suppressed accumulation of lipid droplets in adipocytes through the suppression of adipogenic specific factor peroxisome proliferator-activated receptor (PPAR) γ and fatty acid synthase and activated acetyl-CoA carboxylase. Dietary Calebin-A effectively decreased weight gain and relative perigonadal, retroperitoneal, and mesenteric fat weight in HFD-fed mice. Furthermore, Calebin-A markedly reduced hepatic steatosis and the serum levels of glutamate oxaloacetate transaminase, glutamate pyruvate transaminase, total cholesterol, and triacylglycerol. These effects were associated with the downregulation of PPARγ, sterol regulatory element-binding protein-1, and particularly the activation of AMP-activated protein kinase α signaling found in both adipocytes and liver tissues. Conclusion: Taken together, these results demonstrated for the first time that Calebin-A suppressed adipocyte differentiation, prevented HFD-induced obesity, and improved hepatic steatosis, suggesting a novel application for the prevention and treatment of obesity and associated nonalcoholic fatty liver disease. © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. Source


Majeed M.,Sami Labs Ltd | Nagabhushanam K.,Sabinsa Corporation | Natarajan S.,Sami Labs Ltd | Vaidyanathan P.,Sami Labs Ltd | Karri S.K.,ClinWorld Private Ltd
International Journal of Pharma and Bio Sciences | Year: 2014

Intra Ocular Pressure (IOP) is the fluid pressure inside the eye and is the most important risk factor for glaucoma. From the roots of Coleus forskohlii, an aromatic herb growing all over India, we extracted Forskolin. In this study we studied the IOP lowering activity of two strengths of Ocufors, viz., Ocufors® (Forskolin 1% w/v ophthalmic solution) and Ocufors® (Forskolin 0.15% w/v ophthalmic solution) in 12 New Zealand white rabbits, divided into three groups, four rabbits each. IOP was induced using water loading model in all three groups, as an acute model, with the right eye of all the animals received water for injection and thereby served as reference control. Whereas the left eye on all the three group animals received active drug, with Group 1 animals instilled with one drop of 1% w/v Forskolin solution while Group 2 and 3 animals instilled with one and two drops of 0.15% w/v Forskolin solution respectively. Post instillation of Forskolin 1% w/v ophthalmic solution (one drop), Forskolin 0.15% w/v ophthalmic solution, (one drop) and Forskolin 0.15% w/v ophthalmic solution (two drops) showed an IOP reduction of 23%, 19% and 30% at 45min, 45min and 75min respectively in New Zealand white rabbits, under test conditions employed. Forskolin aqueous clear ophthalmic solution showed a prolonged reducing effect on the IOP with one drop of 1% (w/v). However, a similar effect was noticed with two drops of 0.15% (w/v) Forskolin aqueous ophthalmic solution. Further clinical evaluation and confirmation of the low strength Ocufors (Forskolin 0.15% w/v) ophthalmic solution would help in replacing its higher strength counterpart (Forskolin 1% w/v) in mild open angle glaucoma patients. Source

Discover hidden collaborations